Experimental vaccine aims to tame rare throat tumor disease
NCT ID NCT07317154
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This early-stage trial tests a custom-made vaccine for recurrent respiratory papillomatosis (RRP), a rare condition where non-cancerous growths keep coming back in the throat. The vaccine is made from each patient's own immune cells and designed to target the virus that causes RRP. Nine adults will receive five doses to see if it is safe and sparks an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- autologous dendritic cell vaccine loaded with HPV6 E6/E7 peptides
- What this could lead to
- If successful, this could point toward a treatment that reduces or prevents papilloma regrowth, potentially decreasing the need for repeated surgeries.
- What could go wrong
- This is a very early Phase 1 trial with only 9 participants, so safety and immune response are the main goals—not yet proof of effectiveness. The vaccine may not shrink papillomas or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT RESPIRATORY PAPILLOMATOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.